Latest Conference Articles

Most of the data on vedolizumab has been limited by small sample sizes and short follow-up.

About a quarter of Cologuard's ordered by patients are deemed to be inappropriate.

Infections in patients with ulcerative colitis treated with ozanimod were mostly characterized as non-serious.

The treatment would represent the first microbiota-based live biotherapeutic to show efficacy in the first recurrence of CDI.

Data show adverse outcomes include increased mortality rates, prolonged hospital stay, and higher hospitalization chargers.

Data show global burden of NAFLD increased, while burden of cirrhosis decreased in adolescents and young adults.

Ulcerative colitis patients with fatigue are more likely to be unemployed, have moderate or severe disease, and higher Mayo scores.

Data show males, patients with high BMI correlated with higher FAST score in HCV care.

Data show clinically meaningful improvement in IBDQ score and MCS score in patients treated with UST.

Data show biologic therapy was not associated with ICU admission or death due to infection.

C difficile and sepsis infections can be especially difficult to treat.

SER-109 resulted in a 73% reduction in relative risk for CDI over 8 weeks.

Hospitalizations were more likely in patients with CDI of small bowel and Crohn's disease, with worse outcomes noted in patients admitted to ICU.

There is a substantial health care cost for CDI patients with sepsis.

In data presented at DDW, researchers find a decrease in hospital-acquired CDI infections in 2020 when compared to 2018 and 2019.

More and more individuals are becoming diagnosed with atrial fibrillation. But the research to halt this crisis is not quite there yet.

A survey at ACC 2021 showed 38% of cardiology professionals were burnt out during COVID-19. What factors in the field have already made it difficult to cope?

The high-risk patient population is under-represented in new research and agents. Why characteristics set it apart from other cardiovascular diseases?

New data suggest 90 days following an initial ACS event is the greatest time of likelihood for another high-risk event. How can this inform cardiovascular research?

Marc Bonaca, MD, explains the value of new assessments made in the pivotal peripheral artery disease clinical trial.

A cardiologist and wellness expert discusses new findings showing more than one-third of her peers were burnt out from experiences during the pandemic.

The Duke investigators return to discuss the pivotal study of rivaroxaban in peripheral artery disease.

There is no clear threshold for consumption leading to an AFib event.

Patients with a preserved ejection fraction saw a significant reduction in risk for cardiovascular-related adverse events and mortality.

New phase 2 data show the potential of the biologic in patients at risk of acute pancreatitis progression, but with a need for better variable understanding.

Investigators discuss recently-published secondary sex-based assessments into PCI treatment, as well as their contribution to cardiovascular research action points that lessen the field's disparities.

Patients on atorvastatin experienced similar rates of adjudicated venous thromboembolism and all-cause mortality compared to placebo.

The 1-year follow-up of the REALITY trial presented at ACC undermines previously reported 30-day findings showing noninferiority to liberal transfusions.